On April 25, 2016, the Food and Drug Administration met at the University of Maryland University College to hear pleas from desperate patients, and consider clinical trial data from a Sarepta drug (eteplirsen) that could help those with Duchenne muscular dystrophy.
During presentations to the F.D.A., Stacie Al-Chokhachi embraces her son, Dalton, who has Duchenne muscular dystrophy. Stacie and Dalton came from Memphis to participate in the event and show their support.
A link to the New York Times article is here.